Company Profile
Dermata Therapeutics Stock Price, News & Catalysts
- Ticker:
- DRMA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.46 USD (0.00%)
Close
Last updated: August 17, 2026
5.47M USD
Market cap
Why the stock is moving
The latest monitored headline was “Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules”. DRMA was little changed in the corresponding trading session, closing at $1.46 on Aug 17, 2026.
Company overview
Consumer Skincare Company
Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy.
Tome Brand
Tome is designed as a professional-style at-home skincare line built around simplified, periodic treatments rather than multi-step daily regimens.
Foundational Treatment
The first product is a once-weekly mask intended to support skin renewal and serve as the foundation of the broader Tome portfolio.
Future catalysts
- Commercial launch of Tome Foundational Treatment on August 25, 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Dermata Therapeutics (DRMA)?
Dermata Therapeutics (DRMA) most recently closed at 1.46 USD, a 0.00% move versus the previous session.
What is the market cap of Dermata Therapeutics (DRMA)?
Dermata Therapeutics currently has a market capitalization of 5.47M USD on BioPharmSignal.
What does Dermata Therapeutics do?
Consumer Skincare Company Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy. Tome Brand Tome is designed as a professional-style at-home skincare line built around simplified, periodic treatments rather than multi-step daily regimens. Foundational Treatment The first product...
On which exchange is DRMA stock listed?
Dermata Therapeutics (DRMA) is associated with NASDAQ, United States, Biopharma.
What is Consumer?
Consumer Skincare Company Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy.
Which conditions is Dermata Therapeutics targeting with Consumer?
Dermata Therapeutics is associated with dermatology based on its company overview and current catalyst commentary.
How does Dermata Therapeutics describe recent progress with Consumer?
Commercial launch of Tome Foundational Treatment on August 25, 2026.
What is Skincare?
Consumer Skincare Company Dermata Therapeutics has shifted from clinical-stage dermatology development toward a direct-to-consumer commercial skincare strategy.